Surufatinib FDA Approval Status
FDA Approved: No
Generic name: surufatinib
Company: Hutchison China MediTech Limited
Treatment for: Neuroendocrine Carcinoma
Surufatinib is a novel, oral angio-immuno kinase inhibitor in development for the treatment of pancreatic and non-pancreatic neuroendocrine tumors (“NET”).
Development Timeline for surufatinib
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.